RxDoctor Payments Data

Ishai Ross, MD

Urology · Ft Lauderdale, FLNPI 1225266232

Payments from drug & device makers

$10,990in general payments, 2019–2025

Across 320 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$3K
  • AbbVie$779
  • Procept Biorobotics Corporation$639
  • Coloplast$621
  • Boston Scientific$575
  • Endo Pharmaceuticals Inc.$556
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$2,00018%
  • Travel & lodging$1,12010%
  • Food & beverage$7,63469%
  • Education$2362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,990 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$241,786
Medicare patients
867
Services billed
2,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron578$323,381
ErleadaApalutamide13$193,409
GemtesaVibegron98$74,840
OrgovyxRelugolix11$29,897
Mirabegron ErMirabegron20$12,722
Tamsulosin Hcl728$10,135
Finasteride431$6,151
Tadalafil59$4,804
Alfuzosin Hcl ErAlfuzosin Hcl173$4,086
Testosterone58$3,014
Potassium Citrate ErPotassium Citrate33$2,907
Methenamine Hippurate40$2,522
Testosterone Cypionate36$2,414
Solifenacin Succinate34$1,947
Oxybutynin Chloride ErOxybutynin Chloride78$1,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$523$323,381578 claims
Johnson & JohnsonErleada$547$193,40913 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$130$104,737109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.

Other urology in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →